Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions, Inc. (NYSE: EBS) is a global life sciences company dedicated to protecting and enhancing life. With a mission to secure public health, Emergent develops, manufactures, and distributes a broad portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company is committed to safeguarding lives and aims to protect and enhance 50 million lives with its products by 2025.
Headquartered in Gaithersburg, Maryland, Emergent operates through three primary segments: Commercial, Products, and Services. The Commercial segment, which generates the majority of the company's revenue, includes key products such as NARCAN® Nasal Spray—a life-saving medication for opioid overdoses. NARCAN® has become widely accessible in pharmacies, grocery stores, and online retailers, significantly increasing public availability since its over-the-counter approval by the FDA in March 2023.
Emergent is also known for its role in developing and manufacturing vaccines and therapeutics, particularly for governments and healthcare providers. The company's Baltimore Bayview manufacturing facility recently received a “No Action Indicated” status from the FDA, confirming its compliance with good manufacturing practices. This recognition underscores Emergent's dedication to quality and compliance in its manufacturing processes.
Financially, Emergent is focused on stabilizing its operations and strengthening its balance sheet. The recent restructuring plan aims to streamline operations, close certain manufacturing facilities, and reduce workforce by 300 employees, resulting in annualized savings of approximately $80 million. Despite these changes, Emergent remains dedicated to its core business areas and continues to offer integrated contract development and manufacturing services to pharmaceutical and biotechnology customers.
Key recent developments include the extension of NARCAN® Nasal Spray's shelf life from 36 to 48 months and its widespread distribution across the U.S. and Canada. Emergent is also actively working with partners like the National Safety Council to educate businesses and the public about opioid overdose prevention and response.
Emergent is committed to its long-term vision of protecting and enhancing 1 billion lives by 2030. The company continues to innovate and expand its product offerings while maintaining a strong focus on public health and safety.
Emergent BioSolutions (NYSE: EBS) has received a $50 million contract option from BARDA for its CYFENDUS® anthrax vaccine. The deliveries are scheduled between now and April 2025. This follows a previous $30 million contract modification for the same vaccine. CYFENDUS®, FDA-approved in July 2023, is a two-dose anthrax vaccine for post-exposure prophylaxis in individuals aged 18-65.
The contract strengthens national anthrax preparedness against potential bioterrorist incidents, as anthrax is classified as a Tier 1 biological select agent. Emergent's anthrax portfolio also includes BioThrax® vaccine and two treatments: Anthrasil® and raxibacumab.
Emergent BioSolutions (NYSE: EBS) announced that its antiviral drug brincidofovir (TEMBEXA®) will be included in a clinical trial led by Africa CDC as part of the 'MpOx Study in Africa' (MOSA). The randomized double-blind placebo-controlled trial will evaluate the safety and efficacy of brincidofovir in treating mpox virus. Currently, there are no FDA-approved therapeutics for treating patients with mpox who are at risk of severe complications. While brincidofovir can be used for mpox in the U.S. under emergency Investigational New Drug protocol, this will be its first randomized controlled study for mpox treatment.
Emergent BioSolutions (EBS) reported strong Q3 2024 financial results with total revenues of $293.8 million, up 9% year-over-year. Net income reached $114.8 million, a 144% increase, while Adjusted EBITDA grew 432% to $105.3 million. The company secured significant financing through a $250 million Term Loan and $100 million asset-backed facility. Notable transactions included the $75 million sale of RSDL®, $35 million from Baltimore-Camden site sale, and receipt of $50 million from Janssen dispute resolution. Based on strong performance, EBS raised its FY 2024 guidance, projecting revenues of $1,065-$1,125 million.
Emergent BioSolutions (NYSE: EBS) has appointed Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development, effective November 18. Dr. Lowry brings over 25 years of experience in healthcare and pharmaceuticals, most recently serving as CEO of Mysthera Therapeutics AG. He will oversee research and development, regulatory affairs, medical affairs, clinical and biostatistics, and patient safety. Additionally, Jessica Perl has been promoted to General Counsel and Corporate Secretary after serving in the interim role since August.
Emergent BioSolutions (NYSE: EBS) has scheduled its third quarter 2024 financial results conference call for November 6, 2024, at 5:00 pm eastern time. The call will cover Q3 financial performance, recent business developments, and the company's financial outlook for full year 2024. Participants can join via webcast or telephone, with dial-in numbers provided for both U.S./New York (+1-646-968-2525) and U.S. & Canada toll-free (+1-888-596-4144). A replay will be available on the company's Investors webpage.
Emergent BioSolutions (NYSE: EBS) reaffirms its commitment to combating the opioid epidemic by expanding access to NARCAN® Nasal Spray and educating the public on opioid overdose response. The company is supporting the 'White House Challenge to Save Lives from Overdose' by implementing workplace safety measures and continuing its Ready to Rescue public awareness campaign.
Emergent has installed opioid emergency wall units in its facilities and provided NARCAN® Nasal Spray to employees. The company is also working with partners like the National Safety Council to educate businesses. Since NARCAN® Nasal Spray became available over the counter in August 2023, Emergent has distributed over 2,700 opioid emergency kits on college campuses and in public venues.
In response to recent CDC data showing a decline in opioid overdose deaths, Emergent is pledging to donate an additional 20,000 doses of NARCAN® Nasal Spray to communities in need. The company remains committed to expanding access and awareness through OTC availability, partnerships, and education initiatives.
Emergent BioSolutions Inc. (NYSE: EBS) has announced the closing of a new $100 million asset-backed loan facility (ABL) on September 30, 2024. The credit agreement, with Wells Fargo Bank as the administrative agent, provides revolving loan commitments with a maturity date of September 30, 2029, subject to early maturity triggers. This new facility adds to Emergent's liquidity, supporting its multi-year transformation plan. As of September 30, 2024, Emergent had a cash balance of approximately $150 million and undrawn access to the full $100 million ABL.
Joe Papa, president and CEO of Emergent, stated that the new ABL credit facility with favorable terms and extended maturity demonstrates the company's strengthened balance sheet and financial position. This agreement follows Emergent's recent refinancing of its debt, including a new credit facility agreement with Oak Hill Advisors for a term loan of up to $250 million announced on September 3, 2024.
Emergent BioSolutions Inc. (NYSE: EBS) has announced the execution of two contract options valued at $67.4 million for the procurement of additional TEMBEXA® (brincidofovir) treatment courses. This order supports the U.S. government's national preparedness efforts against human smallpox. The contract options, CLIN0004A and CLIN0005A, are part of Emergent's existing 10-year contract with a maximum potential value of $568 million.
TEMBEXA® is indicated for treating human smallpox disease in adult and pediatric patients, including neonates. The funding, secured through 2027, will ensure a continued supply of TEMBEXA® to address the threat of smallpox. This project is funded by the Department of Health and Human Services, Administration for Strategic Preparedness and Response, and Biomedical Advanced Research and Development Authority (BARDA) under contract number 75A50122C00047.
Emergent BioSolutions Inc. (NYSE: EBS) has secured approximately $400 million in orders for 2024 and 2025 related to its vaccinia, smallpox, and mpox product portfolio. This includes a U.S. government contract modification for ACAM2000® and CNJ-016® (VIGIV) contract options. In 2024, nearly $210 million in orders have been delivered, with an additional $185+ million confirmed for delivery through 2025.
The company recently received FDA approval for ACAM2000® to include mpox prevention in high-risk individuals. Emergent has also submitted an Expression of Interest to the WHO for Emergency Use Listing (EUL) of ACAM2000® for mpox. Additionally, Emergent has donated 50,000 doses of ACAM2000® for potential deployment in affected African countries.
Emergent BioSolutions Inc. (NYSE: EBS) has been awarded a $41.9 million contract modification by BARDA for the continued development of Ebanga™ (ansuvimab-zykl), a licensed treatment for Ebola virus disease. This option is part of a larger 10-year contract valued at approximately $121 million for advanced development and up to $583 million for procurement of Ebanga™ treatment.
The funding will support drug substance engineering, scale-up process validation, long-term stability studies, and commercial readiness. Emergent will also complete post-licensure commitments, including technology transfer for manufacturing scale-up and submission of a supplemental Biologics License Application to the FDA.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
What is Emergent BioSolutions' core mission?
What are the main segments of Emergent BioSolutions?
What is NARCAN® Nasal Spray?
What recent compliance certification did Emergent receive?
What are Emergent's recent restructuring plans?
How is Emergent enhancing the availability of NARCAN® Nasal Spray?
What financial goals does Emergent have?
What is Emergent's vision for the future?
What services does Emergent offer to pharmaceutical and biotechnology customers?
How can stakeholders participate in Emergent's conference calls?
